Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
2018 · Journal of the American College of Cardiology · 459 citations
https://doi.org/10.1016/j.jacc.2018.03.009
A
Anna Norhammar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
238
Papers
15.0K
Citations
51
h-index
99
i10-index
Anna Norhammar is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Diabetes Treatment and Management & Cardiovascular Function and Risk Factors & Diabetes Management and Research. The author has an h-index of 51, co-authored 203 publications.
ORCID: 0000-0002-4467-0132Papers by this author
worksThe impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
2007 · European Heart Journal · 185 citations
https://doi.org/10.1093/eurheartj/ehm518
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( <scp>US</scp> , <scp>UK</scp> and Sweden)
2021 · European Journal of Heart Failure · 155 citations
https://doi.org/10.1002/ejhf.2271
SGLT-2 Inhibitors and Cardiovascular Risk
2018 · Journal of the American College of Cardiology · 129 citations
https://doi.org/10.1016/j.jacc.2018.01.085
SGLT-2 Inhibitors and Cardiovascular Risk
2018 · Journal of the American College of Cardiology · 129 citations
https://doi.org/10.1016/j.jacc.2018.01.085
Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
2016 · Journal of the American College of Cardiology · 106 citations
https://doi.org/10.1016/j.jacc.2016.06.061
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat